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Background: Aortic regurgitation (AR) after TAVI is the main limitation of
this procedure. The aim of this study was to evaluate i) aortic annulus sizing by
CT and/or echocardiography (TTE or TEE) ii) the incidence of AR and its deter-
minism iii) the prognostic impact of AR and other survival predictors.
Methods: 136 consecutive patients undergoing TAVI were included
between 2010 and 2013. The aortic annulus sizing for prosthesis choice was
done by TEE in 29 patients and by CT in 107 patients. Aortic valve calcium
volume was measured by the volume technique in 67% of patients who have
got CT. Follow-up was performed at 1, 6, 12 and 24 months.
Results: Aortic annulus sizing by TTE and TEE echocardiography (TEE)
were well correlated (r=0,73, p=0,0001, n=51) but were significantly lower
than CT sizing (p < 0,0001). The incidence of AR ≥ 2/4 was 13% and was not
significantly different according to the strategy of aortic annulus sizing for
prosthesis choice. No predictor of AR≥ 2/4 was identified. Calcium volume
was not associated either with AR with 1 month mortality. Mortality was 13%
at 1 month, 25% at 1 year and 39% at 2 years. Predictors of mortality at
2years in univariate analysis were Euroscore> 25%, aortic regurgitation ≥ 2/4,
renal failure with creatinin> 130μmol/l, anemia after TAVI < 8g/dl, trans
aortic gradient before TAVI < 30mmHg and tamponade. In multivariate anal-
ysis, independent predictors were aortic regurgitation ≥ 2/4, anemia after
TAVI < 8g/dl and tamponade (OR 2,75 CI 1,3-6,7; OR 2,5 CI 1,1-5,75 et OR
4,5 CI 1,30-15,55 respectively).
Conclusion: This study showed that aortic annulus sizing by echocardiog-
raphy is significantly lower than sizing by CT. AR have an independent prog-
nostic on survival. Prevention of aortic regurgitation is an important issue for
the future of this technique.
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Introduction: The PARTNER trial has shown that TAVI is not inferior to
surgical aortic valve replacement (AVR) in high-risk aortic stenosis. However,
real life registry comparing TAVI and surgery are lacking.
Methods: monocentric registry of high-risk patients (lEUROSCORE1
≥15%) undergoing TAVI (114 patients) or AVR (81 patients) between 2009
and 2013 in our institution.
Results: mean age was 84,4 and 83,6 yo (p=NS). TAVI patients had higher
EUROSCORE1 (31 vs 24.5%, p<0,001), lower LVEF (48,4 vs 57%, p<0,0001)
and lower mean aortic gradient (46 vs 53mmHg, p=0,0001). Mortality in-hospital
was not statistically different between TAVI and AVR; 9,6 vs 17,3% respectively
(p=0,12). TAVI patients presented more vascular complications (11,4 vs 0%,
p= 0,001), needed more Pace-Maker (24,6 vs 4,9%, p<0,0001) but presented less
in-hospital infections (11 vs 19%, p=0,008), less new atrial fibrillation (20 vs 41%,
p=0,002), and needed less transfusions (25,4 vs 80,2%, p<0,0001). 
Conclusion:  the present registry results confirm that TAVI is a real alter-
native to surgery in patients with at high surgical risk. Longer follow up is
required to confirm these results.
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The aim of the study was to assess the prognosis of three different aortic
stenosis populations operated by TAVI: Severe aortic stenosis (SAS), low-
flow low-gradient aortic stenosis (LFLG) and paradoxical low-flow low-gra-
dient aortic stenosis (PLFLG).
Between January 2010 and August 2013, patients with severe symptomatic
aortic stenosis were consecutively referred to our institution, for TAVI because of
multiple comorbidities and excessive surgical risk. We defined and split patients
into 3 populations as followed: PLFLG (iAVA≤0.6 cm2, MG≤40 mmHg,
SVI≤35mL/m2, LVEF≥50%, Zva>4.5 mmHg/mL/m2, MaxV<4m/s), LFLG
(iAVA≤0.6 cm2, MG≤40 mmHg, MaxV<4m/s, LVEF≤50%, SVI≤3 5mL/m2), and
SAS (MaxV>4 m/s, MG>40 mmHg, LVEF>50%). The primary endpoint of our
study was to evaluate global and cardiovascular mortalities; secondary endpoints
included VARC 2 variables. A significant decrease in survival rate regarding the
all-cause mortality (p=0.02) and cardiovascular mortality (p=0.05) was observed
in the LFLG group (n=59) in comparison to the PLFLG (n=31) and SAS (n=172)
groups, which had similar survival rates. Regarding the immediate post-procedural
outcomes, the LFLG group had more CHF (p<0.001) and a higher BNP before
discharge (p=0.009) than the other groups. VARC 2 variables analysis did not
show any significant results. Intrahospital and 30-days mortalities were higher in
the PLFLG and LFLG groups (p=0.05). There was a trend toward an increase in
MACCE in the LFLG group (p=0.13) at one month. TAVI for PLFLG patients is
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AVR TAVI p
n 81 114
Age 83.6 84.4 0.21
Euroscore1 (%) 24.5 31 <0.0001
FEV (%) 57.1 48.5 <0.0001
DTVG (mm) 51 54 0.086
Mean Gradient (mmHg) 53 46 0.008
Creatinin pre (microM/L) 111 138 0.003
Hemoglobin pre (g/100) 12.6 11.6 <0.0001
Death  (%) 17.3 9.6 0.12
Vascular complication (%) 0 11.4 0.001
Infection (%) 19 11 0.008
Dialysis (%) 13.6 11.4 0.65
AFIB post (%) 41 20 0.002
Pericardial effusion (%) 2.5 8.8 0.13
Stroke (%) 4.9 1.8 0.23
Pace Maker (%) 4.9 24.6 <0.0001
Transfusions (%) 80 25 <0.0001
